التفاصيل البيبلوغرافية
| العنوان: |
Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial. |
| المؤلفون: |
Nam-In Kang, Bon-Hoon Koo, Sung-Wan Kim, Jong-Hoon Kim, Beomwoo Nam, Bong-Ju Lee, Sang-Hyuk Lee, Seung Jae Lee, Seung-Hwan Lee, Myung Hun Jung, Sang Woo Hahn, Young-Chul Chung |
| المصدر: |
Clinical Psychopharmacology & Neuroscience; Aug2016, Vol. 14 Issue 3, p261-269, 9p |
| مصطلحات موضوعية: |
DRUG efficacy, PSYCHIATRIC treatment, PSYCHOSES |
| مستخلص: |
Objective: We investigated the efficacy and tolerability of paliperidone extended-release (ER) tablets in patients with first-episode psychosis (n=75). Methods: This was an 8-week, open-label, multicenter trial. The primary outcome variable was scores on the Positive and Negative Syndrome Scale (PANSS); secondary measures included the Scale for the Assessment of Negative Symptoms (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of Functioning (GAF). To assess safety, we measured drug-related adverse events, weight, lipid-related variables, and prolactin and administered the Simpson–Angus Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU). Results: The administration of paliperidone ER resulted in significant improvement in the PANSS, SANS, CAI, and GAF scores (p＜0.001) over time. This improvement was evident as early as 1 week. The most frequent adverse events were akathisia, somnolence, anxiety, and sedation, which were well tolerated. Modest increases in weight and lipid profiles were also noted. Prolactin levels were substantially increased at the endpoint in both male and female patients. Conclusion: These results indicate that paliperidone ER is effective and is characterized by good tolerability in the treatment of positive and negative symptoms and cognitive functioning in first-episode psychosis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Psychopharmacology & Neuroscience is the property of Korean College of Neuropsychopharmacology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder